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Abstract 
Background:  Electrocardiograms in elite endurance athletes sometimes show bizarre patterns suggestive of inherited 
channelopathies (Brugada syndrome, long QTc, catecholaminergic polymorphic ventricular tachycardia) and cardiomyopathies 
(arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy) responsible for unexpected sudden cardiac death. 
Among other methods, genetic analyses are required for correct diagnosis. 
Objective: To correlate 12-lead electrocardiographic patterns suggestive of inherited channelopathies and cardiomyopathies to 
specific genetic analyses. 
Design: Prospective study (2004-2007) of screening 12-lead ECG tracings in standard position and higher intercostal spaces 
V1 to V3 precordial leads, performed in athletes and normal sedentary subjects aged match. Genetic analyses of subjects with ECG 
abnormalities suggested inherited channelopathies and cardiomyopathies. 
Setting:  All cardiologic exams and electrocardiograms were performed at „Prof. Dr. C.C. Iliescu” National Institute of 
Cardiovascular Diseases (Bucharest, Romania). The genetic studies were done at ”Mina Minovici” National Institute of Forensic 
Medicine (Bucharest, Romania). 
Participants: 347 elite endurance athletes (seniors - 190, juniors - 157), mean age of 20; 200 subjects mean age of 21, 
belonging to the control group of 505 normal sedentary population. 
Results: Seniors. RSR’ (V1 to V3) pattern, in 45 cases (23.68%), 5 of them with questionable Brugada sign (elevated J wave 
and „coved” ST segment, < 2mm in one lead, V1. Typically, Brugada 1 sign was found in one case (0.52%) with no SCN5A 
abnormalities. One athlete (0.52%) had normal ECG and exon1 SCN5A duplication. MRI confirmed three arrhythmic right ventricular 
cardiomypathy epsilon waves (1.57%), in one case. ST-segment elevation myocardial injury like in V1-V3 precordial leads in 34 
athletes (17.89%).Genetic analyses-no gene mutations. 
Juniors. Upright J wave was found in 43 cases (27.38%). Convex ST segment elevation in V1-V3/V4, in 39 cases (24.84%). 
Bifid T wave with two distinct peaks was found in 39 cases (24.84%), 5 of them with mild prolonged QTc (0.48”-0.56”) and KCN 
genes mutations. Nine (5.73%) of the elevated ST segment juniors had questionable Brugada sign, two of which with KCN (n=1) and 
SCN5A (n=1) gene mutations. Ajmaline provocative test was negative in 4 and was refused by 5 subjects. 
Conclusion: Bizarre QRS, ST-T patterns suggestive of abnormal impulse conduction in the right ventricle, including the right 
outflow tract, associated with prolonged QTc interval in some cases were observed in highly trained endurance athletes. The genetic 
analyses, negative in most athletes, identified surprising mutations in SCN5A and KCN genes in some cases. 
 
Key words: endurance athlete, electrocardiography, genetic analysis 
The medical society and athletes’ community are 
extremely interested in the precocious identification of 
athletes’ risk of sudden cardiac death. Pre-participating 
screening guidelines for athletic training are formulated by 
many scientific medical groups [1-5,7-10]. The frequent 
causes of sudden cardiac death in athletes younger than 
35 years old are hypertrophic cardiomyopathy (HCM) 
50%, idiopathic left ventricular cardiomyopathy 18%, 
coronary artery abnormalities 14%, arrhythmogenic right 
ventricular cardiomyopathy (ARVC), 2.23-20% [11,57]. In 
3%, sudden cardiac death is associated with normal 
structural hearts. Inherited cardiac channelopathies Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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(Brugada syndrome, long QT syndroms, idiopathic 
ventricular fibrillation, polymorphic ventricular tachycardia) 
could be the causes for sudden cardiac death [11-14]. In 
the absence of any echocardiographic structural 
abnormalities, establishing the diagnosis is often difficult 
to achieve when the electrocardiograms of trained 
athletes often present findings considered abnormal by 
usual standards. The correct management includes 
detailed athlete’s history, 12-lead electrocardiography, 
additional tests (i.e. 24h heart rhythm ambulatory 
monitoring, Ajmaline provocative test) and sometimes, 
targeted genetic analysis [15-18]. A genotype - phenotype 
analysis based on the electrocardiographic findings in 
elite endurance athletes was the purpose of our study. 
Material and methods 
Studied population 
Endurance athletes 
347 intensively trained athletes (Caucasians) 
participants in sports activity with high cardiovascular 
burden were chosen [19,20]. The sports were canoeing, 
rowing, football, hockey, tennis, swimming, and athletics. 
There were 190 senior and 157 junior athletes [20]. 
Senior athletes had trained intensively for 20-27 h /week 
for > 5 years and participated in World Championships 
and Olympic Games. The junior primary and final 
selections were at the age of 12-14 years old and 17-18 
years old respectively. 
 
Sedentary healthy population (controls) 
The apparently normal (asymptomatic, normal 
physical examination, no detectable cardiovascular risk 
factors) sedentary population [21,25] of 505 subjects and 
participants were investigated for work eligibility in our 
Cardiology Department (Auto/Work License). Exclusion 
criteria for control subjects were coronary artery disease, 
valvular / congenital diseases, cardiomyopathies, heart 
failure, and cardiovascular drug therapy. None of the 
athletes and controls received any drugs. The protocol 
was approved by the Hospital Ethical Committee and 
informed consents were obtained from all subjects who 
enrolled in the study. 
 
Study protocol 
Clinical examination 
The cardiologic examination included detailed 
personal and family history and complete physical 
examination [9,11]. 
 
Standard 12 - lead electrocardiography 
ECG was recorded with a digital machine (MACC 
5500 GE Medical Systems, Milwaukee, Wisconsin, USA) 
in all athletes and controls. ECG measurements were 
computer - assisted and independently manually 
controlled by two experienced electrocardiographic 
readers (CM,IS) unaware of clinical data and sports 
categories [22-24,36]. Disagreements regarding the 
measurements were resolved by consensus. An average 
of 3-5 cardiac cycles was used. Tracings were obtained > 
24 hours after the last athletic activity. Recordings in 
higher right precordial V1-V3 intercostal spaces (six new 
positions: -1V1 to -1V3; -2V1 to -2V3) to detect the 
Brugada signs were performed in all athletes and 
sedentary normal subjects [26,27,32]. Ajmaline 
provocative test in standard 12-lead ECG and upper right 
V1-V3 precordial leads positions was indicated according 
to the current guidelines [33,61]. ECG parameters were 
evaluated according to actual criteria [22-24,36]. 
 
Standard electrocardiographic variables. Definitions. 
We used the current electrocardiographic criteria 
[22,23] including: 
1) normal sinus rhythm: heart rate 60-100 bpm; 
2) normal QTc (Bazett) ≤ 0.39”in men , ≤ 0.44” in 
women; 
3) borderline normal ECG : RSR’ or rSr’ pattern in V1 
lead (QRS duration < 0.10”, height < 7mm; r’wave < 2mm 
and r’< r; juvenile T wave (inversed T in V1-V3 precordial 
leads; usually deep < 2mm); 
4) Q wave (≤ 0.5 mm in lead III; normal duration ≤ 
0.03”and height ≤ 0.4 mm in all leads); 
5) J wave (Osborn; deflection that distort the QRS-ST 
junction usually in II,III,V4 to V6 leads); 
6) upright T wave (beyond normal ≤ 0.5 mm in limb 
leads and ≤ 0.10 mm in precordial leads); 
7) bifid T wave (T wave with two peaks different from 
U wave; possible delayed right ventricular repolarization); 
8) ST-segment, normally isoelectric (within normal 
limits: elevation and depression ≤0.1mm in limb leads, 
elevation  ≤0.3 mm in V1-V3 precordial leads; 
measurements at 80 ms from the J point). 
 
ECG patterns in highly trained endurance athletes 
[41-45,47-49,54] 
A.  Distinctly abnormal ECG, strongly suggesting 
cardiovascular disease: 
1) striking increase in R or S wave voltage (≥35mm) 
in any lead; 
2) Q waves ≥4 mm in depth in ≥ 2 leads; 
3) inverted T wave > 2mm in ≥2 leads; 
4) left bundle branch block; 
5) marked left (≥-30º) or right (≥110º) QRS axis 
deviation; 
6) Wolff-Parkinson-White pattern. 
B. Mild abnormal ECG 
1) increased R or S wave voltage (30 to 34mm) in 
any lead; 
2) Q waves 2 to 3 mm in depth, in ≥ 2 leads; 
3) T wave flat, minimally inverted or particularly tall 
(i.e.≥15mm) in ≥2 leads; 
4) abnormal R wave progression in the anterior 
precordial leads; 
5) left atria enlargement; 
6) short PR interval (≤0.12”). 
C.  Normal ECG or ECG with minor alterations 
(athlete’s heart syndrome): 
1) PR interval duration >0.20”; 
2) R or S voltage, 25 to 29mm; 
3) early repolarization; 
4) RSR’pattern in V1 ,V2 of 0.12” in duration); Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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5) sinus bradycardia < 60 bpm. 
For the Brugada syndrome: long QT syndrome, 
polymorphic ventricular tachycardia, ARVC and HCM the 
commonly adopted clinical and electrocardiographic 
criteria were used in the study [30,31,34,35,37-40,47-49]. 
Holter monitoring, indicated when necessary 
[28,29,46]. 
 
Echocardiography 
Echocardiographic, standard Doppler and TDI 
analyses were performed by digital ultrasound machine 
(VIVID 3, GE Medical Systems, Milwaukee, Wisconsin, 
USA; Aloka α Grosound, Japan). 
Measurements were done according to ASE criteria. 
(58) 
 
Genetic study 
Subjects with positive or questionable ECG patterns 
of inherited channelopaties / cardiomyopaties were 
enrolled. 
Techniques. Genomic DNA (200µl blood) - 
QiAampDNA blood minikit (Qiagen). 
SCN5A and KCN genetic mutations studies were 
performed with Multiplex Ligation-Dependent Probe 
Amplification (MLPA, MRC Holland). SALSA P108 for 
SCN5A and SALSA P114 for KCNQ1, KCNH2, KCNE1, 
KCNE2 , kit were used.( 50,51,52,53,54,55,56) 
 
Statistics 
Results are expressed in mean value ± SD. 
Proportions were compared with the chi square test, 
where appropriate. 
Results 
Clinical characteristics of studied population 
We examined 347 athletes (seniors 190; juniors 157). 
Fig. 1 shows the athletes’ distribution according to the 
type of sport and level of training.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Athletes. There were 272 males (78.38%) and 75 
females (21.6%). The athletes group characteristics: age 
19.45 ± 4.82 years old (11-37), height (cm) 178.08 ± 
8.99(140-200), weight (kg) 73.70 ± 12.33 (34-109), BSA 
(m2) 1.90 ± 0.19(1.15 - 2.37), blood pressure (mmHg) 
(110/65-140/85), heart rate (bpm) (32-110).  
Controls. 505 normal sedentary subjects, 284 males 
(56.23%), 221 females (43.75%). Characteristics: age 
34.93±10.88 years old (13-76), height (cm) 170.71±8.46 
(134-195), weight (kg) 68.86±12.25 (29-125), BSA (m2) 
1.79±0.18 (1.14 - 2.41), blood pressure (mmHg)(105/60-
143/85), heart rate (bpm)(42-115).  
The demographic data of the entire cohort of 
sedentary subjects is summarized in Table1, according to 
the decades of age. 
 
 
Age (y)  No. (505)  Height (cm)  Weight (Kg)  BSA (m2)  BP(mmHg) 
mean  HR(bpm) 
13 - 20  21  163.1±12.61  54.5±11.95  1.58±0.23  105/75  84±12 
21 - 30  179  171.27±11.31  67.33±15.05  1.78±0.19  110/75  82±14 
31 - 40  189  171.37±7.53  70.54±14.43  1.83±0.17  120/80  78 ±11 
41 - 50  67  168.66±8.36  70.07±10.14  1.79±0.16  125/75  68 ±15 
51 - 60  35  168.78±8.91  74.12±8.84  1.78±0.35  130/75  72 ±15 
61 - 76  14  172±8.57  77.63±10.34  1.90±0.14  130/85  68±10 
                            Table 1 Sedentary normal subjects group divided by decades of age 
 
Electrocardiographic findings 
All electrocardiographic parameters in athletes 
(n=347) are summarized in Table 2. 
Senior athletes. RSR’ pattern in high V1-V3 
precordial leads in 45 athletes (23.68%) associated with 
ST elevation in 34 cases (17.89%). Coved ST segment 
elevation, suggestive for Brugada 1 sign in one lead only 
(standard/high V1; questionable Brugada sign) in 5 of ST 
elevation subjects. Provocative Ajmaline test – negative in 
2 cases and refused by 3 subjects. Complex premature 
ventricular beats (Holter, 24h), were found in 23 athletes 
(12.10%). 
Brugada sign1, V1-V3 standard / high, one (0.52%) 
subject; EP induced ventricular tachycardia. 
Epsilon wave, was found in 3 athletes (1.57%). Bifid 
T wave associated to prolonged QTc (0.48”± 0.09”) was 
found in 8 athletes (4.21%). 
There was a normal echocardiographic exam except 
for one epsilon subject and for ARVC echo data, 
diagnosed by MRI. 
Athletes distribution by sports, seniors and juniors.
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Fig. 1 190 seniors and 157 juniors athletes and their 
distribution according to type of sport 
No., number, BSA, body surface area, BP, blood pressure,systolic/diastolic; HR, heart rate. Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Junior athletes. RSR’ (R’height 2.18±0.56mm) 
recorded in the V1-V3 upper precordial leads, 26 cases 
(16.56%); questionable Brugada sign in 9 athletes 
(5.73%). Ajmaline provocative test was negative in 4 
cases and refused by 5 subjects. In juniors, the highest 
incidence of 12-leads ECG abnormalities were J wave 
elevation (1.32±0.63mm), 34c (27.38%) and ST-segment 
convex injury elevation (elevation height 2.39±0.79mm, 
measured at 80ms from J point) pattern, 39c(24.84%)  
(Table 2). Bifid T waves associated to prolonged QTc 
intervals (0.56”± 0.07”) were recorded in 5 subjects 
(Table 2). Long QTc associated with coved ST elevation 
in V1 (questionable Brugada sign) in 2 subjects. 
 
 
 
 
 
 
12 lead ECG  Athletes, seniors 
N=190 (%) 
Athletes, juniors 
N=157 (%) 
SR  190 (100)  156 (99.36) 
Arrhyth  23 (12.10)  19 (12.10) 
WPW  1 (0.52)  1 (0.63) 
Std RSR’ V1-V3 (mm)  16 (8.42)      NS  9 (5.73)      NS 
High RSR’ V1-V3 (mm_  45 (23.68) *  26 (16.56) * 
J>0.5 V1-V3 (V4) (mm)  50 (26.31)    NS  43 (27.38)   NS 
ST- segm V1-V3 (V4) (mm)  34 (17.89)    NS  39 (24.84)   NS 
T >15 mm V1-V3 (V4)  23 (12.10)    NS  31 (19.74)   NS 
Inversed T > 2 mm  8 (4.21)        NS  9 (5.73)       NS 
Bifid T wave  23 (12.10)    NS  39 (24.84)   NS 
Epsilon wave  3 (1.57)  - 
Brugada 1 sign  1 (0.52)  - 
Osborn  47 (24.73)  37 (23.56) 
QTc int  (0.48”- 0.56”)  8 (4. 21)  7 (4. 45) 
            Table 2 12-lead ECG parameters in senior and junior athletes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Holter method (for 24h) revealed complex premature 
ventricular beats (n=23 seniors), Wenckebach AV block 
(n=2 seniors), Wolff-Parkinson-White syndrome (one 
senior; one junior). Bicuspid aortic valve (n=1), HCM 
(n=1) and anomalous origin of the RCA from the left 
Valsalva sinus (n=1) recorded on echocardiography. 
Normal sedentary subjects 
According to the decades of age, 505 subjects` ECG 
characteristics are shown in Table 3. In the first 2 
columns, 200 normal subjects (13-20y; 21-30y) match the 
athletes’ age. In this subgroup (13-30 y; n=200) the ECG 
SR, sinus rhythm; Arrhyth, arrhythmias; WPW, Wolff- Parkinson-White; Std RSR’, standard 
RSR’ in V1-V3 leads; High RSR’, higher intercostal spaces; ST- segm, ST-segment elevation 
myocardial injury like; T>15mm, positive T wave >15mm; * p < 0.01; NS, insignificant 
Fig.  2 Senior athlete with spontaneous Brugada sign 1 (arrow) on 12-lead ECG. Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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abnormalities were: RSR’ pattern in the V1-V3 upper 
precordial leads (n= 24; 12% of 200), J wave elevation 
(n=13; 6.5% of 200). In the decade of 31-40 years old,  
one epsilon was recorded and ARVC was diagnosed on  
MRI. Typically Brugada 1 sign was detected in 3 cases 
(decade 21-50y) (Table 3). 
 
 
 
 
12 lead ECG  13-20y 
N=21 
21-30y 
N=179 
31-40y 
N=189 
41-50y 
N=67 
51-60y 
N=35 
61-76y 
N=14 
SR  21 (100) 
(4.15) 
178 (99.44) 
(35.24) 
189 (100) 
(37.42) 
67 (100) 
(13.26) 
35 (100) 
(6.93) 
14 (100) 
(2.77) 
WPW  2 (9.52) 
(0.39) 
3 (1.67) 
(0.59)  -  2 (2.98) 
(0.39)  -  - 
Std RSR’ V1-V3 (mm)  1 (4.76) 
(0.19) 
2 (1.17) 
(0.39) 
6 (3.17) 
(1.18) 
3 (4.47) 
(0.59)  -  - 
High RSR’ V1-V3 (mm)  5 (23.8) 
(0.99) 
19 (10.61) 
(3.76) 
24 (12.69) 
(4.75) 
5 (7.46) 
(0.99) 
1 (2.85) 
(0.19)  - 
J>0.5 V1-V3 (V4) (mV)  1 (4.76) 
(0.19) 
12 (6.70) 
(2.37) 
18 (9.52) 
(3.56) 
7 (10.44) 
(1.38) 
3 (8.57) 
(0.59)  - 
ST- segm V1-V3 (V4) (mV)  -  3 (1.67) 
(0.59)  -  -  -  - 
T >15 mV, V1-V3 (V4)  -  2 (1.17) 
(0.39) 
2 (1.05) 
(0.39) 
1 (1.49) 
(0.19)  -  - 
Inversed T >2 mm  -  8 (4.47) 
(1.58) 
3 (1.58) 
(0.59) 
1 (1.49) 
(0.19)  -  1 (7.69) 
(0.19) 
Epsilon wave  -  -  1 (0.52) 
(0.19)  -  -  - 
Brugada 1 sign  -  1 (0.56) 
(0.19) 
1 (0.52) 
(0.19) 
1 (1.49) 
(0.19)  -  - 
Osborn  4 (19.04) 
(0.79) 
33 (18.43) 
(6.53) 
17 (8.99) 
(3.36) 
9 (13.43) 
(1.78) 
2 (5.71) 
(0.39) 
1 (7.69) 
(0.19) 
Table 3 Electrocardiographic findings in normal sedentary subjects divided by decades of age 
 
Genetic analysis 
227 athletes (114 seniors, 113 juniors) and 35 normal 
sedentary subjects were selected. The 12-lead ECG 
inclusion criteria for genetic analysis were: 
1) Brugada sign; 
2) questionable Brugada sign; 
3) high RSR” precordial leads V1-V3 and R’>2mm >R 
and associated with complex PVB; 
 
4) inverted T waves (>2 mm) in > 2 leads; 
5) bifid T wave with distinct two peaks associated or 
not with prolonged QTc interval; 
6) ST-segment convex elevation, injury like pattern; 
7) epsilon waves. 
In  Fig. 3 the percent of the ECG abnormalities in 
senior and junior athletes selected for genetic analyses 
are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
N.B. Number, first % (related to age decade group) and second % (related to the 505 controls). 
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Fig. 3 ECG abnormalities percent 
in senior (n=114) and junior 
(n=113) athletes referred to 
genetic analysis 
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Seven junior athletes had mutations on KCN genes: 
KCNQ1 (n2), KCNE2 (n1), KCNH2 (n4); all mutations 
were missense (duplication) on exon 2 (n3), exon 4 (n2), 
exon 18 (n1) and exon 19 (n1). One of these athletes 
whose electrocardiograms are presented in Figure 4b,4b’ 
had 2 mutations on 2 different KCN genes (KCNQ1, 
KCNH2) (Fig. 4a). 
None of the senior athletes selected for genetic 
analysis had gene mutations except for one with SCN5 
duplication, exon 1 (Fig. 6); normal clinical exam and 
negative specific tests for Brugada syndrome were done 
in this case. No SCN5A mutations in Brugada sign1 
athlete and EP induced ventricular tachycardia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brug_14
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
1.40
1.50
1.60
1.70
1.80
1.90
2.00
e
1
e
2
e
3
e
4
e
6
e
7
e
9
e
1
1
e
1
5
e
1
7
e
1
9
e
2
1
e
2
2
e
2
3
e
x
2
5
e
2
7
e
2
8
C
0
1
C
0
2
C
0
3
C
0
4
C
0
5
C
0
6
C
0
7
C
0
8
C
0
9
C
1
0
C
1
1
C
1
2
LQT_14
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
1.40
1.50
1.60
1.70
1.80
1.90
2.00
K
C
N
E
2
_
e
1
K
C
N
E
2
_
e
2
K
C
N
E
1
_
e
4
S
C
N
5
A
_
e
2
7
K
C
N
Q
1
_
e
2
K
C
N
Q
1
_
e
3
K
C
N
Q
1
_
e
5
K
C
N
Q
1
_
e
8
K
C
N
Q
1
_
E
1
0
K
C
N
Q
1
_
e
1
2
K
C
N
Q
1
_
e
1
4
_
2
K
C
N
Q
1
_
e
1
6
K
C
N
Q
1
_
e
1
9
K
C
N
H
2
_
e
1
K
C
N
H
2
_
e
3
K
C
N
H
2
_
e
6
K
C
N
H
2
_
e
1
0
K
C
N
H
2
_
e
1
5
Fig.  4a  Junior athlete. MLPA profiles for SCN5A gene (SALSA P108, upper panel) and for KCNQ1 and KCNH2 
(SALSA P114, lower panel). Possible double mutations (duplication) for exon 18 KCNQ1 and exon 4 KCNH2 (Brug. 
SALSA P108; LQT. SALSA P114). Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
  367 
© 2009, Carol Davila University Foundation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Athlete normal genetic profile for SCN5A and KCN genes are shown in Fig.  5. 
Fig.  4b, 4b’ Electrocardiograms of two KCN genes mutations in junior athlete. In standard 12-lead 
ECG sinus rhythm 62 bpm; bifid T waves and distinct two peaks in V2, V3 precordial leads. (arrow) 
In higher V1, V2 leads (one upper) -bifid T waves are evident in V2 (arrow); ( two upper spaces) - 
epsilon wave in V1 (arrow) 
4b 
4 b’ Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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One senior athlete had missense mutation (duplication) on SCN5A gene, exon1 (Fig.  6). 
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Fig.  5 Senior athlete. MLPA profiles for SCN5A gene (SALSA P108, upper panel) and for SCN5A, KCNQ1, 
KCNH2, KCNE1, KCNE2 (SALSA P114, lower panel). No detectable mutations. (Brug. SALSA P108; LQT. SALSA 
P114) 
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Gene mutations and electrocardiographic associated abnormalities in athletes are summarized in Table 4. 
 
 
 
Athletes  KCNQ1  KCNE2  KCNH2  SCN5A  ECG 
1  dup e 18  -  -  -  bifid T wave; QTc  0.52 
2  -  dup e 2  -  -  bifid T wave; QTc  0.56 
3  dup e 19 (19-1;19-2)  -  dup e 4  -  bifid T wave; QTc  0.48-0.50 
4  -  -  dup e 4  -  QTc  0.56 
5  -  -  dup e 2  -  inverted T wave; QTc  0.48 
6  -  -  dup e 2  -  questionable Brugada 
7  -  -  -  dup e 1  questionable Brugada 
             Table 4 Genes mutations and ECG abnormalities in 7 athletes. 
 
In sedentary normal subjects, one subject with 
Brugada 1 sign and his healthy and 
electrocardiographically normal mother had similar 
mutations (deletion) on SCN5A gene, exon1. An epsilon 
sedentary normal subject (decade 31- 40y) had MRI 
documented ARVC; no gene mutations were detected, 
but his clinically and electrocardiographically normal sister 
had missense mutation (deletion) on SCN5A, exon1. 
Discussions 
Since 2004 we have been interested to evaluate the 
ECG patterns in highly trained athletes from different level 
of training (juniors, seniors) involved in sports with 
intensive cardiovascular burden. We observed ECG 
tracings with bizarre and unexpected QRS and ST-T 
aspects, different from the „classically” ECG patterns 
described in elite endurance athletes [20,58-61]. 
The main purpose of our study was to find out 
whether these ECG (V1-V3) morphologies (possible 
delayed impulse conduction in the right ventricle, 
including RVOT) were linked to genetic mutations 
responsible for inherited channelopathies (i.e. Brugada 
syndrome, RVOT ventricular tachycardias) and 
cardiomyopathies (i.e.ARVC). Gene mutations for HCM in 
subjects with specific ECG abnormalities were searched 
for. 
The senior and junior athletes’ electrocardiograms 
were analyzed separately and compared to sedentary 
normal, aged matched persons’ ECG data. In seniors, the 
RSR’ pattern dominate with R’>2mm in higher V1-V3 
leads; 34% of RSR’ athletes had ST-segment elevation, 
resembling the Brugada sign present in only one lead and 
V1 (questionable Brugada sign) in few cases. Possible 
abnormal (delayed) impulse conduction into RVOT has 
been considered regarding this mechanism [49]. 
LQT_10
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
1.40
1.50
1.60
1.70
1.80
1.90
2.00
K
C
N
E
2
_
e
1
K
C
N
E
1
_
e
2
K
C
N
E
2
_
e
2
K
C
N
E
2
_
e
2
K
C
N
E
1
_
e
4
S
C
N
5
A
_
e
4
S
C
N
5
A
_
e
2
7
K
C
N
Q
1
_
e
1
K
C
N
Q
1
_
e
2
K
C
N
Q
1
_
e
2
K
C
N
Q
1
_
e
3
K
C
N
Q
1
_
e
4
K
C
N
Q
1
_
e
5
K
C
N
Q
1
_
e
6
K
C
N
Q
1
_
e
8
K
C
N
Q
1
_
e
9
K
C
N
Q
1
_
E
1
0
K
C
N
Q
1
_
e
1
1
K
C
N
Q
1
_
e
1
2
K
C
N
Q
1
_
e
1
3
K
C
N
Q
1
_
e
1
4
_
2
K
C
N
Q
1
_
e
1
5
K
C
N
Q
1
_
e
1
6
K
C
N
Q
1
_
e
1
8
K
C
N
Q
1
_
e
1
9
K
C
N
Q
1
_
e
1
9
_
2
K
C
N
H
2
_
e
1
K
C
N
H
2
_
e
2
K
C
N
H
2
_
e
3
K
C
N
H
2
_
e
4
K
C
N
H
2
_
e
6
K
C
N
H
2
_
e
7
K
C
N
H
2
_
e
1
0
K
C
N
H
2
_
e
1
1
K
C
N
H
2
_
e
1
5
C
0
1
Fig. 6 Senior athlete. MLPA profiles for SCN5A (SALSA P108, upper panel) – possible exon1 duplication. SALSA 
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The highest incidence of junior ECG abnormalities 
was elevated J wave and convex injury like ST-segment 
elevation in V1-V3,V4 leads (standard, high). In junior 
athletes, bifid T wave associated to moderately long QTc 
interval arose the question of a possible abnormal 
prolonged ventricular repolarization. Few of our controls 
had similar ECG abnormalities. 
A molecular substratum not evident in ordinary life 
but exacerbated by strenuous training could be the cause 
of athletes’ ECG abnormalities. 
To support this hypothesis we focused on the relation 
between the ECG patterns suggestive of Brugada 
syndrome, long QT syndrome, HCM, ARVC and specific 
genetic study. 
The genetic analysis referred to mutations in SCN5A 
and LQTS genes and genes responsible for inherited 
cardiomyopathies. 
Junior athletes had 7 mutations in LQTS genes 
(KCNQ1, KCNH2, KCNE2) one of them with two KCN 
mutations, on KCNQ1 and KCNH2. All seven 
abnormalities were missense (duplication) mutations on 
exons 2 ,4, 18 and 19.  
Three controls had SCN5A mutations: two of these 
(deletions) were in 1 Brugada person and his healthy 
mother. Interestingly, a family member (healthy sister) of 
a documented ARVC patient had a SNC5A mutation 
(duplication). All SCN5A mutations were missense, 
heterozygote type. 
No specific molecular abnormalities were found in 
other athletes. 
The mutations identified by MLPA will be detailed by 
complex genetic analyses such as the sequence 
techniques. 
Conclusions 
The electrocardiogram in athletes performing high 
endurance training is sometimes strange, looking like 
inherited channelopathy and cardiomyopathy ECG 
patterns. Specific tests for correct diagnosis are frequently 
necessary. Genetic analysis, the „last step” to diagnosis 
sometimes gives surprising and unexpected information, 
whose significance needs to be investigated. Complex 
molecular techniques could bring forward details of these 
genetic mutations identified in elite athletes with 
„frequently encountered 12-lead ECG athletics patterns”. 
The next and future medical approach regarding the 
athletic performance is still a challenge for the scientific 
medical community. 
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